ANTITUMOR EFFECT OF SUNITINIB AND BORTEZOMIB ON BREAST CANCER CELL LINE IN VITRO

ORIGINAL ARTICLES. B. EXPERIMENTAL RESEARCH

https://doi.org/10.37469/0507-3758-2017-63-1-141-145

Published 01.01.2017

Yuliya Khochenkova⁺⁻
Eliso Solomko⁺⁻
Oksana Ryabaya⁺⁻
Yevgeniya Stepanova⁺⁻
Dmitriy Khochenkov⁺⁻

Yuliya Khochenkova

N.N. Blokhin Russian Cancer Research Center Moscow

Eliso Solomko

N.N. Blokhin Russian Cancer Research Center Moscow

Oksana Ryabaya

N.N. Blokhin Russian Cancer Research Center Moscow

Yevgeniya Stepanova

N.N. Blokhin Russian Cancer Research Center Moscow

Dmitriy Khochenkov

N.N. Blokhin Russian Cancer Research Center Moscow

##article.numberofdownloads## 60

##article.numberofviews## 54

PDF (Русский)

Keywords

BREAST CANCER
SUNITINIB
BORTEZOMIB
КОМБИНИРОВАННАЯ ТЕРАПИЯ IN VITRO
COMBINED THERAPY IN VITRO

How to Cite

Khochenkova, Y., Solomko, E., Ryabaya, O., Stepanova, Y., & Khochenkov, D. (2017). ANTITUMOR EFFECT OF SUNITINIB AND BORTEZOMIB ON BREAST CANCER CELL LINE IN VITRO. Voprosy Onkologii, 63(1), 141–145. https://doi.org/10.37469/0507-3758-2017-63-1-141-145

Abstract

The discovery for effective combinations of anticancer drugs for treatment for breast cancer is the actual problem in the experimental chemotherapy. In this paper we conducted a study of antitumor effect of the combination of sunitinib and bortezomib against MDA-MB-231 and SKBR-3 breast cancer cell lines in vitro. We found that bortezomib in non-toxic concentrations can potentiate the antitumor activity of sunitinib. MDA-MB-231 cell line has showed great sensitivity to the combination of bortezomib and sunitinib in vitro. Bortezomib and sunitinib caused reduced expression of receptor tyrosine kinases VEGFR1, VEGFR2, PDGFRa, PDGFRß and c-Kit on HER2- and HER2+ breast cancer cell lines

https://doi.org/10.37469/0507-3758-2017-63-1-141-145

##article.numberofdownloads## 60

##article.numberofviews## 54

PDF (Русский)

References

Adams J. The proteasome: a suitable antineoplastic target // Nat. Rev. Cancer. - 2004. - Vol. 4. - P. 349-360.

Aderhold, C., Faber A., Umbreit C. et al. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy // Anticancer Res. - 2015. - Vol. 35. - P1389-1399.

Banerjee S., Dowsett M., Ashworth A., and Martin L.-A. Mechanisms of disease: angiogenesis and the management of breast cancer // Nat. Clin. Pract. Oncol. - 2007. - Vol. 4. - P. 536-550.

Bergh J., Bondarenko I.M., Lichinitser M.R. et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. - 2012. - Vol. 30. - P. 921-929.

Crown J.P., Diéras V., Staroslawska E. et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. - 2013. - Vol. 31. -P. 2870-2878.

Deshaies R.J. Proteotoxic crisis, the ubiquitin-protea-some system, and cancer therapy // BMC Biol. - 2004. - Vol. 12. - P. 94.

Foroni C., Broggini M., Generali D., and Damia, G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact // Cancer Treat. Rev. - 2012. - Vol.38. - P. 689-697.

Jansson S., Bendahl P.-O., Grabau D.A. et al. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRa, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer // PLoS ONE. - 2014. - Vol. 9. - e102176.

Mendel D.B., Laird A.D., Xin X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic / pharmacodynamic relationship // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. - 2003. -Vol.9. - P. 327-337.

Powers G.L., Rajbhandari P., Solodin N.M. et al. The Proteasome Inhibitor Bortezomib Induces an Inhibitory Chromatin Environment at a Distal Enhancer of the Estrogen Receptor-a Gene // PLoS ONE. - 2013. - Vol. 8. - e81110.

Schmid P., Kühnhardt D., Kiewe P. et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/ or anthracyclines // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO - 2008. - Vol. 19. - P. 871-876.

Sorolla A., Yeramian A., Valls, J. et al. Blockade of NFkB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells // Mol. Oncol. -2012. - Vol.6. - P. 530-541.

Trinh X.B., Sas L., Van Laere S.J. et al. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer // Oncol. Rep. - 2012. - Vol.27. - P. 657-663.

Yeramian A., Sorolla A., Velasco A. et al. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezo-mib by blocking Akt pathway // Int. J. Cancer. - 2012. - Vol. 130. - P. 967-978.

Yerlikaya A., Altikat S., Irmak R. et al. Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells // Mol. Med. Rep. - 2013. - Vol. 8. - P. 277-281.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.